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Abstract
Background: The postoperative typing of thyroid lesions, which is instrumental in adequate patient treatment, is
currently based on histologic examination. However, it depends on pathologist’s qualification and can be difficult in
some cases. Numerous studies have shown that molecular markers such as microRNAs and somatic mutations may
be useful to assist in these cases, but no consensus exists on the set of markers that is optimal for that purpose.
The aim of the study was to discriminate between different thyroid neoplasms by RT-PCR, using a limited set of
microRNAs selected from literature.
Methods: By RT-PCR we evaluated the relative levels of 15 microRNAs (miR-221, −222, −146b, −181b, −21,
−187, −199b, −144, −192, −200a, −200b, −205, −141, −31, −375) and the presence of BRAF(V600E) mutation
and RET-PTC1 translocation in surgically resected lesions from 208 patients from Novosibirsk oblast (Russia)
with different types of thyroid neoplasms. Expression of each microRNA was normalized to adjacent non-
tumor tissue. Three pieces of lesion tissue from each patient (39 goiters, 41 follicular adenomas, 16 follicular
thyroid cancers, 108 papillary thyroid cancers, 4 medullary thyroid cancers) were analyzed independently to
take into account method variation.
Results: The diagnostic classifier based on profiling of 13 microRNAs was proposed, with total estimated
accuracy varying from 82.7 to 99 % for different nodule types. Relative expression of six microRNAs (miR-
146b, −21, −221, −222, 375, −199b) appeared significantly different in BRAF(V600E)-positive samples (all
classified as papillary thyroid carcinomas) compared to BRAF(V600E)-negative papillary carcinoma samples.
Conclusions: The results confirm practical feasibility of using molecular markers for typing of thyroid
neoplasms and clarification of controversial cases.
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Background
Nodular thyroid lesions are the most frequent endocrine
pathology. Thyroid nodules are diagnosed in over 5 % of
the adult population and can be subdivided into benign
adenomas or malignant lesions (carcinomas). Carcin-
omas, requiring mandatory surgery, only make up about
5 % of all neoplasms.
Carcinomas are derived from two types of hormone-
producing cells; follicular cells and parafollicular C-cells.
More than 95 % of the thyroid carcinomas originate
from follicular cells and can be grouped into three main
categories: papillary thyroid carcinoma (PTC), follicular
thyroid carcinoma (FTC) and anaplastic thyroid carcin-
oma (ATC). Medullary thyroid carcinomas (MTC) are
derived from the parafollicular C-cells, they account for
a minority (3 %) of thyroid carcinomas [1, 2].
Post-operative histopathology examination of resected
thyroid samples is instrumental to making correct de-
finitive diagnosis. This analysis is never 100 % accurate
and heavily relies on the pathologist’s qualification and
experience. The problem is exacerbated by the fact that
accurate histopathological examination requires profes-
sional performance of biopsy sampling and a large num-
ber of well-prepared histological micropreparations,
which is not always achievable in routine practice. Thus,
there is a pressing need for improving post-operative
subtyping of thyroid nodules. Clearly then, identification
of specific molecular markers should help to increase the
robustness and objectivity of typing. The most recognized
markers in current use are somatic mutations (BRAF
V600E, mutations of isoforms RAS) and translocations
(RET-PTC1, PAX8-PPAR γ). However, not always somatic
changes enabling the accurate classification of neoplasms
can be identified. MicroRNAs (miRNAs) can also serve as
such markers, since recent studies showed that expression
of many of these is always subject to profound changes in
various types of thyroid neoplasms (Table 1).
Three things should be kept in mind: first, even
though it was shown that concentration changes of sev-
eral miRNAs may serve as informative indicators of thy-
roid nodule malignancy itself, these values are not
sufficiently informative for accurate typing of malignant
neoplasms (for instance, see [14, 15]); second, lists of
miRNAs demonstrating significant expression changes
in specific thyroid neoplasms show limited overlap in
different reports. This may partially be attributable to
both differing efficiencies of detection methods used (as
in [16]) and to biases and errors intrinsic to histological
and immunohistochemical analysis serving as a refer-
ence. Third, a recent study [17] revealed the presence of
several discrete subclasses of PTCs, some of these sub-
classes, statistically less often represented in the total
Table 1 Deregulation of miRNA expression in different types of thyroid tumors according to some literature data
Cancer type miRNA Expression Detection method Reference
Papillary thyroid carcinoma (PTC) 187, 221, 222, 146b, 155,
122a, 31, 205, 224
Up-regulated RT-qPCR [3]
146b, 181b, 21, 221, 222 Up-regulated RT-qPCR [4]
221, 222 Up-regulated RT-qPCR [5]
146, 221, 222 Up-regulated microarray, RT-qPCR [6]
221, 222, 181b Up-regulated microarray, RT-qPCR [7]
146b, 221, 222 Up-regulated RT-qPCR [8]
221, 222, 21, 31,
181b, 223, 224
Up-regulated microarray, RT-qPCR [9]
218, 300, 292, 345, 30c Down-regulated microarray, RT-qPCR [9]
Follicular variant of papillary carcinoma (FVPTC)/PTC 146b-3p, 146-5p, 221, 222
375, 551b, 181-2-3p, 99b-3p
Up-regulated microarray, RT-qPCR [10]
Medullary thyroid cancer (MTC) 323, 370, 129, 137, 10a,
124a, 224, 127, 9, 154
Up-regulated RT-qPCR [3]
183, 375 Up-regulated RT-qPCR [11]
Follicular thyroid carcinoma (FTC) 187, 224, 221, 339, 183, 222 Up-regulated RT-qPCR [3]
199b-5p, 144-5p,
144-3p, 199b-3p
Down-regulated microarray, RT-qPCR [12]
192, 197, 328, 346 Up-regulated microarray, RT-qPCR [13]





Down-regulated microarray, RT-qPCR [12]
miRNAs shown in boldface type were used in our work
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sample, were characterized by expression profiles signifi-
cantly different from the others.
The purpose of this work is to develop a classifier
based on the PCR quantification of a limited number of
microRNAs in the surgically excised thyroid tissue. Such
an analysis used in addition to histological examination
is intended for improving the reliability of typing thyroid
neoplasms, including clarification of ambiguous results
of histological analysis. Therefore, we planned to pay
special attention to controversial cases, where the result
of the analysis with the help of the developed classifier
was at variance with the result of the histological report.
For this purpose, we planned to assess the difference
in the content of several pre-selected miRNAs in the
samples from patients with different types of thyroid tu-
mors identified histopathologically; and based on the
analysis of the results to develop miRNA classifier for
molecular subtyping of thyroid neoplasms.
According to the literature data, increased expression
of miR-146b, −221, −222, −181b, and −21 is characteris-
tic of PTC. These, as well as miR-187, were selected as
candidates in our work aimed at increasing the accuracy
of differential diagnosis of papillary cancer. Fewer data
are available for follicular thyroid carcinoma (FTC) and
follicular adenoma (FA), and so the major goal here is to
discriminate reliably between FA and the rest of the be-
nign nodules. Based on the information presented in
Rossing et al. [12], we selected miR-199b-5p and 144-5p
so as to enable differential diagnosis of follicular tumors.
Next, miR-192 [13] was chosen as a marker that would
help discriminate between FTC and FA. Several add-
itional miRNAs were also tested, based on the pro-
nounced histological difference between these tumor
types, namely capsular and/or vascular invasion, charac-
teristic of follicular thyroid carcinoma [18]. Follicular
subtype is also relatively more prone to metastasis. This
property largely results from the invasiveness of cancer
cells, which in turn relies on the process of
epithelial-mesenchymal transition (EMT). Thus, the
above-mentioned additional miRNAs included miR-
200a/b, −205, −141-3p and −31, as the former two
were reported to control EMT [19, 20] whereas miR-
200 is also known to inhibit angiogenesis [21]. miR-
141-3p was chosen for it belongs to the same family
as miR-200, and miR-31 was demonstrated to negatively
regulate cell invasiveness [22]. Finally, consistent with the
recent findings, miR-375 was selected as a candidate
marker for differential diagnosis of medullary thyroid car-
cinoma (MTC) [11]. Thus, our final set of miRNAs in-
cluded miR-221-3p, −222-3p, −146b-5p, −181b-5p, −21-
5p, −187-3p, −199b-5p, −144-5p, −192-5p, −200a-3p,
−200b-3p, −205-5p, −141-3p, −31-5p, −375.
As additional markers, we intended to use the detection
of point mutation in BRAF (V600E) and RET-PTC1
translocation, which most frequently occur in patients
with PTC. In the case of contradictory results (a funda-
mental difference in the histological report and identifica-
tion of a neoplasm made by the miRNA classifier)
detection of one of these markers in the sample may con-
firm the malignancy of the neoplasm.
Methods
Clinical samples
This study was approved by the ethics committee of the In-
stitute of Molecular Biology and Biophysics, Siberian
Branch of the Russian Academy of Medical Sciences. Surgi-
cal material was obtained in compliance with the legisla-
tion of the Russian Federation, and written informed
consent was provided by all the patients. 208 tissue samples
from thyroid nodules were surgically resected from pa-
tients undergoing thyroidectomy (28 men and 180 women,
median age 54 and 56 years, respectively). The samples,
collected between 2011 and 2013, represent a workflow of
a house surgeon during about 2.5 years. Samples had not
been pre-selected intentionally, so the proportion of lesion
types reflects the real distribution of thyroidectomy cases
in the setting of study. Nevertheless, due to various rea-
sons, mostly technical, 12 patients were excluded from
analysis, including one case of anaplastic thyroid carcinoma
and one case of poorly differentiated squamous cell carcin-
oma. Adjacent non-tumor thyroid tissue served as a con-
trol. Special care was taken to ensure that no adjacent
normal tissue was present in the tumor sample, and vice
versa. Sample collection and histology analysis were
controlled by a qualified oncologist (Oncology depart-
ment VI, Novosibirsk Municipal Clinical Hospital #1).
Upon resection, tissue samples were immediately placed
in EverFresh RNA solution (SILEX, Russia) and stored
at +4-8 °C for up to a week until processed. Demographic
and clinical characteristics of the samples are shown in
[Additional file 1].
Histopathology analysis
Tissue samples were processed according to the stand-
ard protocol, i.e., tumor pieces and regional lymph nodes
were fixed in 10 % neutral buffered formalin, dehydrated
in a graded series of alcohols, cleared in xylol and embed-
ded in paraffin. 5 μm thick paraffin sections were stained
with hematoxylin and eosin. This was followed by light
microscopy imaging (5 slides per sample on average).
Analysis of all samples was carried out by staff histologists
of the “Municipal Clinical Hospital No. 1”, we used
the diagnoses given to the patients. Some samples
were independently analyzed at the Railroad Clinical
Hospital (JSC Russian Railways, Novosibirsk) by an
independent expert with work experience of more
than 20 years.
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RNA isolation
500 μL of guanidine lysis buffer (4 M guanidine isothio-
cyanate, 25 mM sodium citrate, 0.3 % sarkosyl, 3 % DTT
aliquoted in oxygen-free atmosphere, supplied by Vector-
Best, Russia) was added to 50 mg of tissue. The sample
was vigorously mixed and left in a thermal shaker for
15 min at 65 °C. Next, the tube was centrifuged at 10000 g
for 2 min, the supernatant was transferred into new vials,
followed by addition of an equal volume of isopropanol.
Reaction was thoroughly mixed and left at room
temperature for 5 min. After centrifugation for 10 min at
12000 g, the supernatant was discarded, and the pellet was
washed with 500 μL 70 % ethanol and 300 μL acetone.
Finally, the RNA was dissolved in 200 μL of deionized
water. If not analyzed immediately, RNA preparations
were stored at −20 °C until further use.
miRNA detection
To quantify miRNA, we followed the protocol published
by Chen and co-authors in 2005 as it allows highly sen-
sitive and specific identification of mature miRNAs. This
protocol includes reverse transcription of mature
miRNA using long stem-loop primer, which is followed
by detection of cDNA via RT-qPCR [23]. Reverse tran-
scription reactions were set individually for each miRNA
to be quantified. The obtained cDNA was used for fur-
ther PCR analysis immediately.
Synthetic analogs of miRNAs
Synthetic analogs of miRNAs were ordered from Biosan
(Russia) and stored frozen in TE at −20 °C until needed.
When used as controls, miRNA analogs were dissolved
in deionized water and added directly into RT reaction
mix, omitting the purification/isolation steps.
Oligonucleotide primers and probes
All oligonucleotides, including dual-labeled probes, were
produced by Vector-Best (Russia). Oligonucleotide se-
quences were designed using online software tool Pri-
merQuest (Integrated DNA Technologies, USA). Several
sets of primer and probe combinations were designed
for each miRNA, and those showing high reverse tran-
scription and PCR efficiencies were used for all down-
stream analyses. Efficiency of reverse transcription was
assessed using quantification cycle (Cq) values obtained
on synthetic miRNA analogs with known concentra-
tions. Amplification efficiency (E) for each primers/
probe combination was calculated by plotting a calibra-
tion curve over a series of RNA dilutions, with RNA iso-
lated from clinical samples showing high levels of the
miRNA of interest. E values ranged from 83.5 to 98.5 %
for different miRNA amplifications. Sequences of primers
and the probe are listed in Additional file 2. Sets of oligos
for miR-146b, −181b −221 detection were validated by
commercially available reagents TaqMan MicroRNA As-
says (Applied Biosystems, USA). Within the linear range,
the difference between Cq of our systems and Applied
Biosystems not exceed 2. The difference in the efficiency
of the reaction did not exceed 3.5 %.
Reverse transcription
Total volume of each reaction was 30 μL. Reaction mix
contained 3 μL of RNA preparation, 21.6 % trehalose, 1x
RT buffer (Vector-Best, Russia), 0.4 mM of each dNTP,
1 % BSA, 100U M-MLV reverse transcriptase (Vector-
Best, Russia), 0.2 μM of appropriate RT primer. Reaction
was incubated for 15 min at 16 °C and 15 min at 42 °C,
which was followed by heat inactivation for 2 min at 95 °C.
3 μL of RT mix was used per one RT-qPCR reaction.
Real-time PCR
Real-time PCR was performed using CFX96 thermal cy-
cler (Bio-Rad Laboratories, USA). All reactions were set
up manually. Total volume of each reaction was 30 μL
and encompassed 3 μL of cDNA, 1x PCR buffer (Vector-
Best, Russia), 0.4 mM of each dNTP (Biosan, Russia), 1 %
BSA, 1U Taq polymerase (Vector-Best, Russia) pre-mixed
with active center-specific monoclonal antibody (Clon-
tech, USA), 0.5 units of uracil-DNA glycosylase (Vector-
Best), 0.5 μM of each primer and 0.25 μM of dual-labeled
probe. PCR cycling conditions were as follows: 2 min in-
cubation at 50 °C, pre-denaturation step at 94 °C – 2 min,
followed by 50 cycles of denaturation (94 °C for 10 s),
annealing and elongation (60 °С for 20 s).
U6 snRNA served as an internal normalization control
because it is most commonly used for this purpose in
studies on the expression of miRNA [24]. Fold change in
expression of each miRNA in the tumor vs normal tissue
was calculated using the following formula which takes




1þEU6ð ÞCq;U6 tumorð Þ
1þEmiRð ÞCq;miR tumorð Þ
1þEU6ð ÞCq;U6 normð Þ
1þEmiRð ÞCq;miR normð Þ
E stands for amplification efficiency of miRNA or U6
internal control, and Cq - quantification cycle.
Reactions with Cq above 37 were considered as nega-
tives. All experimental runs included NTCs (non-tem-
plate controls) for each miRNA analyzed. NTC’s were
run in triplicates. In our hands and with the equipment
used, the Cq values for NTC’s always exceeded 37.
For each patient, miRNAs were profiled in 3 different
samples from thyroid tumor tissue and in 3 different
samples of matching adjacent non-tumor tissue; average
values were taken into analysis.
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Detection of BRAF(V600E)
Detection of BRAF(V600E) mutation was performed using
allele-specific PCR with dual-labeled probe. Sequences of
primers and the probe are listed in Additional file 2. PCR
cycling conditions were as follows: pre-denaturation step
95 °С – 2 min, followed by 50 cycles of denaturation (94 °С,
10 s), annealing and elongation (60 °С, 15 s). Sensitivity of
mutant allele detection, as assessed using samples with
known wild-type and mutant sequences, was 0.75 % (data
not shown). In cases where a mutation was detected, but
no histology report stated “papillary carcinoma,” the
presence of the mutation was confirmed by massive parallel
sequencing on the platform 454 Junior (Roche).
Sequencing
Design of libraries of amplicons and sequences of primers
for analysis with Roche GS Junior
The amplification of the BRAF gene was carried out in
two rounds. In the first round fusion primers were used,
consisting of sequences flanking BRAF V600E mutation
(GATCCAGACAACTGTTCAAAC and ATCTCATTTT
CCTATCAGAGCAA), and attached to their 5′-ends
adaptor sequences “U13” (GCGGTCCAAAAGGGTCA
GT) and “U9” (TTAATATTGCCACGGGCCTA). In the
second PCR round fusion primers were used, consisting
of auxiliary sequences of the Junior platform, and “U13”
and “U9”, located at their 3′ends.
Sequencing
The sequencing was performed on the GS Junior instru-
ment using Titanium kits and following the standard
200 nucleotide flows protocol according to the manufac-
turer’s recommendations.
Data analysis
The initial data analysis was carried out using software
of the manufacturer (GS Run Processor, Roche), accord-
ing to the preconfigured set of filters “Amplicons”, and
then using application software Amplicon Variant
Analyzer v. 3.0 (Roche).
Detection of RET-PTC1 translocation
Detection was performed using Real-time PCR com-
bined with reverse transcription reaction in a single
tube. Total volume of each reaction was 30 μL. Reaction
mix contained 3 μL of RNA preparation, 16.7 % trehal-
ose, 1x RT-PCR buffer (Vector-Best, Russia), 0.4 mM of
each dNTP, 1 % BSA, 100U M-MLV reverse transcriptase
(Vector-Best, Russia), 1U Taq polymerase (Vector-Best,
Russia) pre-mixed with active center-specific monoclonal
antibody (Clontech, USA), 0.5 μM of each primer and
0.25 μM of dual-labeled probe. RT-PCR protocol: incuba-
tion at 45 °С - 30 min., heating at 95 °С - 2 min., 50 cycles
of denaturation at 94 °С - 10 s, annealing and elongation:
60 °С - 20 s. Sequences of primers and the probe are listed
in Additional file 2.
Results
Measurements of miRNA levels in thyroid neoplasm vs
adjacent non-tumor tissue
Histological report classified the 208 surgical samples as
follows: goiter - 39 samples, FA – 41 samples, FTC – 16
samples, PTC – 108 samples (out of them 16 were
FVPTC and the rest were a classical variant of PTC),
MTC – 4 samples. The distribution of different types of
tumors over the sampling with a clear predominance of
papillary cancer reflected a real flow of samples sent to
the pathomorphology examination.
Median fold changes observed for each of the miRNAs
tested in tumor vs matching non-tumor tissue control
from the same patient are summarized in Table 2 (see
also Additional file 3, where data for individual patients
are provided). These data clearly indicate that relative
levels of miRNAs in neoplasms are indeed subject to ex-
tensive changes, and magnitude of those changes may be
correlated with the specific neoplasm subtype. For in-
stance, increased relative expression of miR-221, −222,
−146b, −21, −181b and −187 was reported elsewhere for
classic PTC, and this was indeed observed in our experi-
ments. Pronounced fold changes in expression of miR-
221, −222 and -146b were found in most PTCs, whereas
miR-21 and -181b showed increased expression in about
one third of cases. The increased level of miR-21 was
observed in 38 out of 92 (41 %) samples classified as
PTC, and in 3 out of 16 (19 %) samples classified as
Table 2 Median values of miRNA fold changes in tumors
relative to the adjacent non-tumor tissue, as found in different
histology-classified tumor subtypes
miRNA PTC MTC FTC FA Goiter
21 5.21 3.88 1.35 1.03 1.04
221 16.32 11.42 9.14 1.20 −1.31
222 16.34 11.88 4.30 −1.18 −1.47
205 2.00 −26.13 −12.14 −1.76 −1.47
146b 58.82 −1.62 1.40 −1.35 −1.02
181b 3.70 2.20 1.34 1.22 1.04
200a 1.36 1.71 −1.39 −2.70 −1.92
200b 1.40 1.63 −1.17 −2.42 −1.91
31 6.03 −10.66 −8.39 −3.22 −2.05
187 7.51 2.88 0.07 1.02 −1.38
199b −2.21 −99.73 −56.15 −39.49 −12.12
141 1.39 −1.07 2.01 1.22 −1.38
144 −4.81 −33.51 −2.97 −3.19 −6.19
192 −1.52 −2.81 0.01 −1.55 −2.38
375 12.93 95.00 −1.66 −4.14 −2.32
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FVPTC. The increase of the miR-181b level was ob-
served in 27 out of 92 (29 %) samples classified as PTC,
and in 4 out of 16 (25 %) samples classified as FVPTC.
miR-375 is known to be heavily overexpressed in MTC
and also in PTС [10]. Our data are in line with these ob-
servations, we found that miR-375 displayed increased
expression in about half of PTC samples. miR-199b and
−144 were supposed to serve as markers of follicular
neoplasms, which we do not confirm. Nor do our results
confirm miR-192 as a marker of FTC, as this miRNA
showed little expression changes across tumor types. Fi-
nally, in order to discriminate between follicular thyroid
adenomas and carcinomas, we intended to use miR-
200a/b, −141, −205, and −31. Neither of these miRNAs
turned out to behave as expected: relative expression
changes were uniform yet very subtle for miR-141
whereas the rest of the candidates showed extensive
variation in expression restricted to only a minority of
tumor samples. Notably, follicular neoplasms consist-
ently displayed reduced relative levels of miR-205 and
−31; in contrast, the opposite trend was observed for
PTC where these miRNAs were expressed at higher level
than in the normal tissue (in 30–40 % of samples).
Assessment of the method variation and the choice of
the threshold values for microRNA level changes
In order to estimate the variation of the whole procedure
of analysis, several pieces of adjacent non-tumor thyroid
tissue were lysed, and three equal aliquots of the lyzed
material were independently processed according to the
RNA extraction protocol. This provided us with an esti-
mate of how much relative levels of each miRNA varied
among the technical replicas (Table 3). Note that the
values for 95th and 99th percentiles are equal. In different
replicas, calculated relative values of miRNA levels turned
out to vary up to 5.5-fold, which reflects the maximum
level of differences, which could be attributed to purely
technical reasons rather than to biological variance.
Next, to assess the total measurement error, three dif-
ferent pieces of adjacent non-tumor thyroid tissue from
the same patient were independently processed and their
values were compared. Table 4 summarizes median fold
differences between replicas of a normal thyroid sample
from a single donor, as well as 95th and 99th percentiles
of the dataset. In our hands, the range of these fold
change values typically lies within 1.5-2, however in sev-
eral instances 10–15 fold difference was observed. Based
on these numbers, threshold values of miRNA fold
changes were selected (Table 4), so that the values below
this threshold would not be considered reliable, as they
may be fully attributable to cumulative method variation
(including biological variation).
Diagnostic characteristics of relative miRNA level changes
In each neoplasm subtype we estimated diagnostic char-
acteristics of individual miRNA fold changes as stand-
alone markers, using histopathology report as a reference
method and the selected threshold values as cutoffs. In
Table 5, the results for the most informative miRNAs are
shown. Sensitivity indicates in what percentage of samples
related to some type of neoplasm, according to the histo-
logical conclusion, recorded a significant change in the
amount of the miRNA. It should be noted that the max-
imum sensitivity values (80–90 %) are characteristic of
carcinomas (leaving MTC out of consideration due to the
small amount of samples), in benign neoplasms the
Table 3 Variation of measured levels of different miRNAs in
technical replicas from the same tissue sample
miRNA Median fold change 75th percentile 95th and 99th percentiles
181b 1.28 1.44 1.67
187 1.29 1.43 1.83
205 1.52 1.90 2.39
222 1.51 2.04 2.39
200a 1.67 2.28 2.79
221 1.67 2.44 2.85
146b 1.69 2.28 3.39
199b 1.78 2.79 3.43
21 1.88 2.87 3.56
31 1.64 3.43 5.62
Table 4 Fold changes in measured miRNA levels, as assessed for







124 1.71 4.76 5.21 5.21 5.5
221 1.52 4.02 5.16 5.91 6.0
191 1.47 4.66 5.70 5.70 6.0
21 1.46 4.57 5.93 6.31 6.5
31 1.64 4.66 6.06 6.19 6.5
200b 1.60 4.08 5.50 6.02 6.5
181b 1.40 3.18 5.23 7.78 7.0
187 1.48 3.34 4.59 7.57 7.0
192 1.60 4.13 5.82 6.68 7.0
199b 1.57 5.13 7.01 7.84 7.5
222 1.47 3.96 6.23 7.18 7.5
200a 1.62 4.59 7.21 8.40 8.0
205 1.55 4.48 7.24 8.00 8.0
146b 1.62 4.84 8.31 8.91 8.5
141 1.55 5.21 7.73 8.63 8.5
144 1.67 4.68 9.58 9.99 10.0
375 2.03 11.08 15.35 16.80 15.5
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change in the level of miRNA is mostly recorded in
20–50 % of the samples.
miRNA classifier for molecular subtyping of thyroid
neoplasms
As can be seen from the Table 5, the increase in the rela-
tive levels of single miRNAs (miR-146b and −31) can
serve as a possible criterion for differential typing of
PTC. However, the rest of the tested miRNAs failed to
show high sensitivity and specificity values. One could
expect that neoplasm types could be more reliably
discriminated based on the combinatory information
on fold changes of several miRNAs. So we proposed
classifier constructed as a decision tree that would
help to accomplish this goal, based on the combinatorial
patterns of miRNA expression changes. In Table 6, this
Table 5 Diagnostic characteristics of relative miRNA expression levels as applied to thyroid cancer subtyping
Cancer type miRNA Expression level Specificity (%) Sensitivity (%) PPV (%) NPV (%)
PTC (n = 108) 21 Up 99.00 37.96 97.62 59.64
221 Up 83.00 81.48 83.81 80.58
222 Up 92.00 75.93 91.11 77.97
205 Up 98.99 26.85 96.67 55.37
146b Up 100.00 88.89 100.00 89.29
181b Up 95.00 27.78 85.71 54.91
31 Up 100.00 48.45 100.00 65.28
187 Up 90.00 50.00 84.38 62.50
375 Up 94.90 49.06 91.23 63.27
MTC (n = 4) 21 Up 79.90 25.00 2.38 98.19
221 Up 50.00 75.00 2.86 99.03
222 Up 57.35 75.00 3.33 99.15
205 Up 83.25 75.00 8.11 99.41
31 Down 84.49 75.00 9.38 99.37
187 Up 69.12 25.00 1.56 97.92
199b Down 47.06 100.00 2.70 100.00
144 Down 74.51 100.00 5.45 100.00
375 Up 72.64 66.67 3.51 99.32
FTC (n = 16) 221 Up 51.04 68.75 10.48 95.15
222 Up 55.21 25.00 4.44 89.83
205 Down 86.39 68.75 29.73 97.06
31 Down 86.36 53.33 25.00 95.60
187 Up 68.75 25.00 6.25 91.67
199b Down 49.74 93.75 13.51 98.96
FA (n = 41) 205 Down 83.23 22.50 24.32 81.76
200a Down 90.97 37.84 50.00 85.98
31 Down 86.36 29.73 34.38 83.65
199b Down 51.20 73.17 27.03 88.54
144 Down 73.49 26.83 20.00 80.26
200b Down 87.95 34.15 41.18 84.39
Goiter (n = 39) 200a Down 87.10 21.62 28.57 82.32
31 Down 84.31 21.05 25.00 81.13
199b Down 46.43 53.85 18.92 81.25
144 Down 75.60 35.90 25.45 83.55
192 Down 95.24 20.00 50.00 83.33
200b Down 86.31 28.21 32.35 83.82
PPV positive predictive value, NPV negative predictive value
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classifier is provided as well as its estimated diagnostic
characteristics.
Out of 15 initially selected miRNAs, 13 miRNA species
turned out to be informative for thyroid cancer subtyping,
namely: miR-221, −222, −146b, −181b, −21, −187, −199b,
144, −200a, −200b, −205, −31, −375. As it follows from
the data presented in the Table 6, patterns composed from
information on expression changes in 9 miRNAs allow
highly accurate discrimination between papillary and me-
dullary thyroid carcinomas and the rest of the thyroid neo-
plasms, even though our data are somewhat preliminary
for MTC due to the small sample size. The lowest PPV
and sensitivity were reached for FA. However, the original
histopatology report proved to be the least reliable just for
FA diagnosis (see section “Second opinion on the samples
with conflicting subtyping data” and “Discussion”).
Detection of BRAF(V600E) mutation
All thyroid neoplasm samples were tested for the presence
of BRAF V600E mutation, which was reported to be
prevalent in papillary and anaplastic thyroid carcinomas,
unlike in FTC and benign thyroid nodules [26–28].
BRAF(V600E) mutation was only found in the samples
that were classified as PTC by miRNA profiling (61.7 %
samples). Out of this samples 61 were classical PTC (67 %
of classical PTC), and 5 (31 % of FVPTC) were FVPTC.
Importantly, BRAF(V600E)-positive PTC samples were
significantly different in the relative expression of six
miRNA species from BRAF(V600E)-negative PTCs (Fig. 1).
Four of these miRNAs (miR-146b, −21, −221 and −222)
were upregulated in all 65 PTC samples from
BRAF(V600E) + subgroup, whereas at least one of these
miRNAs showed unaltered or even reduced relative
expression in some of the samples from BRAF(V600E)-
subgroup. In adjacent non-tumor tissues, this mutation
was not detected in none of the cases.
Detection of RET-PTC1 translocation
All samples have been tested for the presence of RET-
PTC1 translocation, which is a recognized molecular
marker for papillary cancer. This is not the only transloca-
tion variant of the RET gene translocation but it appears to
be the most common one [29]. RET-PTC1 translocation
was only detected in samples of papillary cancer (12 %).
Out of this samples 11 were classical PTC (12 % of classical
PTCs), and 1 (6 % of FVPTCs) were FVPTC; notably, in
tissues adjacent to tumors, in which this translocation was
detected, it was also found, albeit in much smaller quan-
tities than in tumor tissues (on average, 70-fold), similar
results are mentioned in [30]. In others samples this trans-
location has not been detected in any adjacent non-tumor
tissues. In full accordance with the literature data, in none
of the samples we detected the simultaneous presence of
BRAF (V600E) mutation and translocation of RET-PTC1.










PTC (n = 108) miR-21, −221, −222, −205, −
146b, −31, −187, −181b, −375
Levels of miR-146b or −31 are increased,
alternatively levels of at least 3 out of
the remaining miRNAs are increased/
level of miR-31 is not reduced
98.00 92.59 98.04 92.45
MTC (n = 4) miR-21, −221, −222, −187,
−375, −205, −31, −199b, −144,
miR-146b level are not increased At least
two miRNAs out of miR-21,- 221, −222, −
187, −375 are above normat least 3 miRNas
out of miR-205, −31, −199b, −144 display
reduced expression
99.51 75.00 75.0 99.51
FTC (n = 16) miR-221, −222, −187, −205,
−31, −199b, −144, −375
Expression levels of miR-21, 146b, 205, 375
are not increased Expression levels of miR-
221 or −222 or −187 are increased Expression
level of miR-199b is reduced Of miR-205,
−31, −144, −375, at least one miRNA
shows reduced expression
99.48 81.25 92.86 98.45
FA (n = 41) miR-205, −200a, −200b,
−31, −199b, −144 -375
Expression levels of miR-21, −221, −222,
−200b are not increased Of miR-181b,
−187, −375 one species at most shows
increased expression Of miR-205, −200а,
−200b, −31, −199b, −144, −375
levels of at least two miRNAs is reduced







Expression levels of miR-21, −146b, −221
or −31 are increased, alternatively any
two species out of miR-222, −205,
−181b, −187, −375 show increased
expression levels
96.59 90.83 97.32 88.54
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Second opinion on the samples with conflicting
subtyping data
For some samples, the initial histological report expli-
citly contradicted the result of the test based on miRNA
classifier. Several reasons could have accounted for this
issue. On the one hand, our molecular approach could
be biased. On the other hand, initial histological analysis is
also prone to errors, which include failures to subtype fol-
licular neoplasms and to discriminate between follicular
form of papillary carcinoma and truly follicular thyroid
neoplasms. In the Russian clinical practice, histological re-
port on the type of thyroid neoplasm is usually made once.
Fig. 1 Comparison of fold changes in expression level of selected miRNAs between BRAF(V600E)-positive and negative PTC samples. Square – median,
box - interquartile range, whisker – non-outlier range. Statistical significance is evaluated using Mann–Whitney U test
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Therefore, an error committed by a pathologist can re-
main undetected throughout the entire treatment of the
patient. In order to understand which of these scenarios is
the most likely in our study, the samples with conflicting
sub-typing data were sent for a blind second opinion to an
independent expert pathologist. Data from the first and
second histology reports, as well as molecular sub-typing
data, are presented in the Table 7.
Diagnosis from the secondary pathology report
matched the miRNA profiling data for 13 samples
(62 %), in one case (Sample No. 175) the second diagno-
sis and the diagnosis based on miRNA are supported by
the detected translocation of RET-PTC1. Only in two in-
stances (9.5 %) the second opinion contradicted miRNA
profiling data yet agreed with the initial pathology re-
port. In one of these cases (sample #123, which was
twice classified as a goiter), BRAF(V600E) was found,
which is typically absent from the benign nodules [31,
32]. In four cases (19 %), the second opinion was in con-
flict both with the first pathology report and with
miRNA typing data; at least for one of these samples
(#164), both histology-based conclusions may raise
doubts, as BRAF(V600E) mutation was detected and
confirmed by 454 sequencing. Finally, in the two
remaining samples, the results of second opinion hist-
ology analysis were inconclusive.
Discussion
Data presented in the Table 7 clearly illustrate possible
inaccuracies of histological analysis and a contribution
of human bias into the final diagnosis and typing of thy-
roid malignancies. Although medical expert consultation
often makes it possible to correct the error of the initial
histological report, our practical experience shows that
the human factor remains a significant source of diag-
nostic inefficiency. Limitations of the “classical” morpho-
logical analyses, used in both pre- and post-operative
subtyping of thyroid tumors are quite well-recognized.
Hence many efforts are currently being undertaken to
develop molecular diagnostic tools (including those
based on miRNA profiling) to sub-type thyroid neo-
plasms. The list of proposed molecular cancer-specific
markers encompasses point mutations in BRAF and
RAS; RET/PTC and PAX8/PPARγ rearrangements; sets
of miRNAs, for which significant changes in expression
have been established for different types of neoplasms;
transcripts of protein-coding genes as well as their prod-
ucts, etc. [33–35].
By now, a lot of data has been accumulated about
changes in the expression of various miRNA in thyroid
tumors. The problem is complicated by the fact that data
from different publications are not always consistent
with each other and it remains unclear whether miRNA
profiling can effectively be used for practical typing of
thyroid tumors. This inconsistency may be attributed to
several reasons.
a) different platforms used to determine miRNA
amount in clinical samples can vary in the efficiency
of detection of specific individual miRNAs (see, for
Table 7 Results of the first and second histological reports for 21 thyroid tumor samples whose miRNA profiles conflicted with the
first histological analysis










8,15,30,141,184 FA PTCa FVPTC - -
28,97 FA PTC FVPTC + -
122,132 Goiter PTC FVPTC - -
170 FTC PTC PTC + -
175 Goiter PTC PTC - +
183 FA FTC FTC - -
168 Goiter FA FA - -
68 FA FTC FA - -
123 Goiter PTC Goiter + -
191 Goiter FTC FA - -
164 FA PTC Goiter + -
106 FA PTC Goiter - -
5 FA FTC Goiter - -
179 Goiter PTC Goiter/FA - -
27 FA PTC Goiter/FA - -
aThe criteria used herein fail to discriminate follicular variant of papillary thyroid carcinoma (FVPTC) from the rest of the PTC subtypes
miRNAs shown in boldface type were used in our work
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example, [16, 36–38]). Currently, there is no
methodology that would be a “gold standard” in
measuring miRNA. The method for extracting the
nucleic acid is also essential. It is important to keep
in mind, that when measuring the value of relative
content of miRNAs in tumor tissue by PCR-based
method, a cumulative bias is likely to occur,
which is aggravated by the following factors: i)
natural (biological) variation of miRNA levels both
in tumor tissue and in the adjacent tissues, e.g.,
age-related changes [39]; ii) sampling errors, i.e.,
contamination of the normal tissue with tumorous
cells, and vice versa, as well as natural heterogeneity of
the tissue being analyzed; iii) variance due to
handling and storage conditions; iv) variance due
to RNA extraction procedure; v) RT and PCR effi-
ciency variance; and vi) not perfect specificity of
the test, i.e., the ability to identify only miRNAs
of interest, but not the molecules with a similar
structure. In our hands, the factors affecting most
strongly the cumulative measurement variation
were nucleic acid extraction step and heterogeneity of
tissue samples. The rest of the factors showed negligible
effects on the measurement accuracy (data not shown).
We believe that observed magnitude of technical
variance (see Tables 3 and 4) is unlikely to be
caused by the RNA isolation procedure, so natural
variation in miRNA levels, or errors during sample
collection may be the contributing factors. These
factors should affect the end result regardless of
the platform used to measure miRNA. Given that
sample collection was beyond our direct control,
we had to choose the threshold values so that
cumulative contribution from technical errors is
minimized.
b) Principles of processing raw data obtained in the
evaluation of the content of miRNAs in a clinical
samples aimed at their integration into the algorithm
of typing may be different. This applies to the selection
of the normalizer, the principles of calibration in
quantitative evaluation, selection of cutoffs for
clinically significant values, etc.
c) Differences between the results obtained by different
groups may result from regional specifics of the
samples, or from the study of a too limited number
of samples, or of only a few types of tumors. I.e.,
vast majority of studies employing miRNA profiling
for differential diagnostics of thyroid malignancies
primarily focus on PTC due to the high prevalence
of this lesion subtype and relative ease of diagnostics
via morphology means. However, when only the
features of papillary carcinoma are analyzed and
compared with normal tissue, molecular characteristics
common to papillary cancer and other types of
neoplasms are overlooked and, therefore, a
classifier based on the analysis of samples of
PTC may mistake for it other types of thyroid
neoplasms.
In our work we did not intend to look for new onco-
genic miRNA in thyroid, but used those of them for
which the changes in the level have previously been re-
vealed in thyroid neoplasms, selecting a set in such a
way as to distinguish between papillary, follicular and
medullary thyroid carcinomas and, whenever possible,
follicular adenoma.
First, we wanted to determine what results could be
obtained on a local sample, because to the best of our
knowledge no such study had been carried in Russia be-
fore ours, and to compare our findings with literature
data. Our data appeared largely in agreement with those
obtained by other researchers. Thus, our results fully
confirm that the increased level of miR-146b is an exclu-
sive and specific tumor marker for PTC with sufficient
sensitivity. On the other hand, in some cases the specifi-
city, which we observed in the changes of the miRNA
levels in different types of neoplasms was at variance
with the published data. Examples of such differences
are presented below:
miRNA-221, −222 – increase in the number of miRNA
in our hands was characteristic of all carcinomas
though in varying degrees: PTC – 81.5 % and 76 %,
respectively, MTC – about 75 %, FTC – 69 % and
25 %. In [3] an increase in miR-221 in MTCs was not
reported.
miRNA-205 – according to [3] its level should rise for
PTC, which is confirmed by our results (the increase
was observed in 27 % cases), and in patients with
conventional FA, which we cannot confirm. In our
study, a reduction in its level has more often been
recorded, i.e., MTC – 75 %, FTC – 69 %, FA – 22.5 %,
PTC – 9.3 % of cases.
miRNA-31 – increase in the level of this miRNA was
observed for PTC [3, 9] and FA [3], in our sample the
increase was observed solely in PTC cases (48 %). On
the other hand, its level often decreased in the cases of
MTC, FTC (53 %) and of FA (30 %).
miRNA-199b-5p – this miRNA was chosen to
discriminate FA and FTC [12]. Indeed the level of
its expression is reduced in 94 % of FTC cases and
73 % FA cases, but also in 100 % MTC cases, 39 %
of PTC cases and 54 % of goiters.
miRNA-375 – Increase in its level tends to be
associated with MTC [11], which we can confirm,
and also with PTC [10], which is also confirmed by
our findings (increased was observed in 49 % cases).
Decrease in its level we recorded for FTC in 19 %
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cases, and in 22 % of FAs. Interestingly, the relative
level of miRNA-375 in non-tumor tissue adjacent to
the medullar cancer tissue was significantly higher (on
average, 68-fold) than in non-tumor tissues adjacent to
any other type of neoplasms.
miRNA-200a, −200b – based on their reported
functions [19, 21], we assumed that their level would
be reduced to a greater extent for FTC cases. Indeed,
more often, their level was reduced (38 and 34 % of
FA cases and in 21 and 19 % of FTC cases), although
in some samples of PTC (8 and 9 %) and FTC (7 and
6 %) we observed the increase in their content.
These differences in the evaluation of the specificity of
changes in the content of certain miRNAs with results
of other studies are by no means unexpected. Firstly, we
used fairly high threshold values, above which changes
in the content of miRNAs we considered reliable (for ex-
ample, for the miR-146b only an increase in comparison
with the control more than 8.5 times was seen by us as
reliable). To the best of our knowledge, most of the
studies in this field were not considered a variation of
the procedure of analysis as a whole, from the dissection.
We believed that using high threshold values was to in-
crease the specificity of discrimination of tumor types,
perhaps at the cost of some desensitization. Secondly,
we used for normalization non-tumor adjacent tissue
from the same patient, in which the level of certain miR-
NAs could in itself have been different from the refer-
ence values determined for healthy tissue. We chose this
strategy because it is more accurate and practically
implementable under the surgical removal of the thyroid
tissue for the postoperative typing.
On the basis of the obtained data and taking into ac-
count the selected threshold values we have managed to
develop a classifier based on the analysis of miRNA and
enabling the discrimination of neoplasms with suffi-
ciently high specificity. Indeed, we have succeeded in
distinguishing different types of carcinomas from each
other and from benign neoplasms with sufficient accur-
acy. Despite the fact that these criteria may have to be
updated as new cases are added, they still make it pos-
sible to clarify some controversial situations arising at
postoperative typing of neoplasms due to the impact of
the human factor and because of the ambiguity of the
classification itself, especially regarding follicular tumors.
The problems associated with the discrimination of
follicular thyroid neoplasms, especially ETC. and FA are
all too known. Our current understanding of the data
concerning chain of molecular events accompanying the
progress of follicular adenoma into carcinoma is far
from complete; neither can we tell which morphological
characteristics of this transformation can be definitive for
a pathologist. For example, the presence of a mutation in
a single isoform of the RAS gene can be indicative of an
increased potential for the FA transformation to FTC
[40, 41], but in follicular adenomas with detected RAS
mutations no clear morphological differences have been
identified from those, in which such mutations have not
been detected. Thus, we speculate that higher resolution
of molecular diagnostic tools, as compared to the histo-
logical analysis, may underlie the discrepancy between the
results of the two approaches.
The fact that molecular classifiers similar to the one
proposed by us demonstrate comparatively inferior diag-
nostic characteristics with regard to follicular neoplasms
can be attributed to the heterogeneity of samples classi-
fied histologically such as FA, FTC, or FVPTC. On
assessing the diagnostic characteristics of our classifier,
the histological report served as a reference method, but
it is clear that some samples can initially have been mis-
typed by histological analysis. Also it should be empha-
sized that in itself the classification of thyroid tumors is
by no means established. Discussions are currently un-
derway suggesting its revision due to the new data relat-
ing to molecular genetics of thyroid tumors [17, 42].
It should be noted that in most cases of contradictions
between the initial histological report and molecular typ-
ing, the initial report was a benign tumor and molecular
diagnosis confirmed by the secondary diagnosis was
cancer (12 out of 20 cases when our classifier indicated
cancer). Only in five cases we found somatic mutations
indicative of papillary carcinoma and confirming the
correctness of typing via miRNA classifier. Undoubtedly,
the list of somatic mutations that occur in thyroid can-
cer is much wider than these two. It should be empha-
sized, however, that it is generally assumed that only
mutations in the BRAF gene and translocation RET-PTC
are specific for PTC (and generated by those anaplastic
cancers) while other genetic changes often observed in
PTC patients (first of all, mutations of RAS) can also be
detected in cases of FA and FTC, and, accordingly, their
detection would be unable to demonstrate the error of
the pathologist's report.
On analyzing the entire sample, we actually detected
BRAF (V600E) mutation and translocation RET-PTC1
translocation only in PTC with a frequency correspond-
ing to the literature data: BRAF (V600E) mutation was
found in 61.7 % of PTC samples (it was observed in 30–
83 % cases, according to [43], RET-PTC1 translocation –
in 12 % cases (occurs in 2.5–87 % cases [44–46]). Thus,
these two markers together were found in 2/3 cases of
PTC. It should be noted that for all samples with de-
tected mutation, the profile of miRNA expression
changes, according to our classifier, clearly points to the
PTC. In addition, relative levels of several miRNA spe-
cies in BRAF(V600E)-positive PTCs are significantly
higher than in BRAF(V600E)-negative papillary cancers.
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This trend has been previously noted for several miR-
NAs from this list (see [47, 48]), however, other studies
fail to support these observations [49, 50]. The inconsist-
encies found thus far may be attributable to both distinct
miRNA detection methods, as well as to the peculiarities
of the samples.
The proposed miRNA classifier proved to be the most
accurate precisely for PTC. It should be emphasized that
PTC represents the majority of malignant neoplasms of
the thyroid gland. Most errors of pathology reports are
associated with its follicular variant. Thus, in our study,
in seven cases of initial pathology reports FVPTC was
apparently mistaken for FA. We believe that for papillary
cancer, the maximum diagnostic reliability both in the
preoperative and postoperative typing using the data of
the analysis of molecular markers will be able to exclude
most of errors arising when only histological report is
taken into account.
The high relevance of using molecular markers for im-
proving the reliability of typing thyroid neoplasms is uni-
versally recognized nowadays. Thus, since 2015 ATA
recommends to identify genetic markers such as muta-
tions of RAS isoforms, mutation of BRAF V600E, trans-
location RET-PTC, PAX8-PPARγ in refining uncertain
cytology results and to take into account the result of
the analysis in the further patient management. In rela-
tion to clinical relevance of miRNA deregulation the
available information is still insufficient, but it should be
emphasized that virtually every case of malignant trans-
formation of thyroid tissue is accompanied by changes
in the expression profile of miRNAs. At the same time,
even for the best studied type of tumors (PTC) it is not
always possible to identify the specific somatic muta-
tions, despite the considerable list of mutations known
to date [17]. Moreover, the identification of the entire di-
versity of these genetic changes, including not only point
substitutions, but also large-scale restructuring of the
genome requires the use of a complex variety of ap-
proaches, while the set of diagnostically significant miR-
NAs is relatively limited, and may be uniformly analyzed
by simple methods, such as those based on PCR.
We believe that molecular typing of thyroid neoplasms
based on the use of miRNAs offers practical prospects,
because it can rely on a limited set of markers while
employing such simple method as RT-PCR, i.e., it does
not require special equipment and professionals with
significant experience. Undoubtedly, additional studies
may be required in order to come to a consensus on
what set of RNAs is optimal for characterizing of differ-
ent types of thyroid tumors. However, even with allow-
ance for the obvious limitations of our work due to a
limited sampling and not too wide set of the analyzed
markers as well as the absence of multicenter validation
of the developed classifier, our results show that typing
of thyroid neoplasms using microRNA profiling can be a
self-sufficient approach. Specific features of such typing
enable it to complement morphological typing even
without additional analysis of somatic mutations For ex-
ample, it was found that, our classifier does not distin-
guish between classical PTC and its follicular variant,
(while the set of characteristic somatic mutations for
these variants is significantly different) [17], but their
distinction by means of histological analysis presents a
certain problem, so that the follicular variant of PTC
is often confused with follicular neoplasms, including
follicular adenomas.
Conclusions
Our data, as well as the results from other groups, argue
for the practical feasibility of improved typing of thyroid
neoplasms via miRNA profiling by means of simple clas-
sifiers in addition to the histological analysis. Even if
histological analysis includes the parallel identification of
somatic oncogenic mutations, the use of microRNAs
may imply additional gain in accuracy.
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